<- Go Home

TELA Bio, Inc.

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Market Cap

$31.6M

Volume

155.7K

Cash and Equivalents

$39.5M

EBITDA

-$32.8M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$54.7M

Profit Margin

67.72%

52 Week High

$2.20

52 Week Low

$0.50

Dividend

N/A

Price / Book Value

-6.07

Price / Earnings

-0.88

Price / Tangible Book Value

-4.89

Enterprise Value

$49.8M

Enterprise Value / EBITDA

-1.54

Operating Income

-$33.8M

Return on Equity

616.62%

Return on Assets

-28.72

Cash and Short Term Investments

$39.5M

Debt

$57.8M

Equity

-$5.2M

Revenue

$80.8M

Unlevered FCF

-$13.6M

Sector

Health Care Equipment and Supplies

Category

N/A

Company Stock Pitches